Quizartinib with Decitabine and Venetoclax

A Phase I/II Study of Quizartinib in Combination With Decitabine and Venetoclax for the Treatment of Patients With Acute Myeloid Leukemia (AML)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1/2
Enrollment
73 patients (estimated)
Sponsors
MD Anderson Cancer Center
Collaborators
National Cancer Institute (NCI)
Tags
BCL-2 Inhibitor, Hypomethylating Agents (HMA), Tyrosine Kinase (TK) Inhibitor
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1553
NCT Identifier
NCT03661307

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.